EGFR and lung carcinoma: Importantly, we provide molecular and cellular evidence demonstrating that PYCR1 is functionally implicated in EGFR- and TLR-driven lung cancer progression, highlighting its potential as both a biomarker and a therapeutic target for lung cancer.